Reference to what was published in the news under “Avigan® Approved for COVID-19 Treatment in Malaysia”, Agility would like to announce that the Malaysian Ministry of Health’s Drug Control Authority has approved Avigan® for use in treatment of COVID-19 patients.
Earlier this year, Global Response Aid (GRA), an affiliate of Agility, and Dr. Reddy’s Laboratories signed an agreement for exclusive global production, distribution and commercialization of the drug with its developer, FujiFilm Toyama Chemical.
Agility cannot assess the financial impact at the moment.
Get real-time air & ocean freight quotes and access to a powerful dashboard.
Kuwait-based Agility Logistics Parks customers can log-on to view contracts and make payments.
UK MOD personnel can log-in to the GRMS portal to schedule household relocation shipments.
Makhazen Reports Q2 2026 Results
Learn More
Download Report
Get real-time air & ocean freight quotes and access to a powerful dashboard.
Kuwait-based Agility Logistics Parks customers can log-on to view contracts and make payments.
UK MOD personnel can log-in to the GRMS portal to schedule household relocation shipments.
Commenting on published news
Reference to what was published in the news under “Avigan® Approved for COVID-19 Treatment in Malaysia”, Agility would like to announce that the Malaysian Ministry of Health’s Drug Control Authority has approved Avigan® for use in treatment of COVID-19 patients.
Earlier this year, Global Response Aid (GRA), an affiliate of Agility, and Dr. Reddy’s Laboratories signed an agreement for exclusive global production, distribution and commercialization of the drug with its developer, FujiFilm Toyama Chemical.
Agility cannot assess the financial impact at the moment.
Sincerely,
Investor Relations Team
Latest Financial News
August 16, 2026
Makhazen Q2 2026 Earnings Webcast
August 16, 2026
Makhazen’s BOD results
August 9, 2026
Board of Directors Meeting Date
August 9, 2026
Disclosure related to an associate result
July 14, 2026
Clarification on Unusual trade
June 10, 2026
Supplement Disclosure related to legal case